TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 728 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
¿Cuál es el ratio P/E de Transmedics Group Inc (TMDX)?
El ratio P/E de Transmedics Group Inc es 129.3679
¿Quién es el CEO de Transmedics Group Inc?
Dr. Waleed Hassanein es el President de Transmedics Group Inc, se unió a la empresa desde 1998.
¿Qué tal es el rendimiento del precio de la acción TMDX?
El precio actual de TMDX es de $112.17, ha disminuido un 1.51% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Transmedics Group Inc?
Transmedics Group Inc pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de Transmedics Group Inc?
La capitalización bursátil actual de Transmedics Group Inc es $3.8B
¿Es Transmedics Group Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 15 analistas han realizado calificaciones de análisis para Transmedics Group Inc, incluyendo 7 fuerte compra, 9 compra, 4 mantener, 0 venta, y 7 fuerte venta